Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
Human Genome Sciences's potential cancer drug mapatumumab failed in a midstage study, the company said Wednesday.
There was no difference in disease response or progression-free survival rates between patients receiving the drug for multiple myeloma and the control group, the company said.
Human Genome Sciences Inc. said it expects to report full results from the study at a scientific meeting later in 2010.
Multiple myeloma is a cancer that affects bone marrow.